Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide for adult ...
FDA approved triplet therapy for relapsed/refractory LBCL, including specific subtypes, for patients ineligible for auto-HSCT or CAR T-cell therapy. The therapy includes brentuximab vedotin, ...
B-cell anomalies play a role in the pathogenesis of membranous nephropathy. B-cell depletion with rituximab may therefore be noninferior to treatment with cyclosporine for inducing and maintaining a ...
Significant uptake of rituximab biosimilars in Medicare and Medicaid occurred within the first 4 years of marketing in the US. Objectives: This study evaluated the uptake and costs of 3 biosimilars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback